Estulic monotherapy and combined antihypertensive therapy

Area of Science:

• Cardiology
• Pharmacology

Background:

• Hypertension is a prevalent condition requiring effective long-term management.
• Estulic (guanfacin) is an antihypertensive agent.
• Assessing the long-term efficacy and safety of Estulic is crucial.

Purpose of the Study:

• To evaluate the antihypertensive effect of Estulic over a 12-month period.
• To determine Estulic's efficacy in monotherapy and combination therapy for different hypertension severities.
• To assess changes in laboratory parameters and subjective complaints.

Main Methods:

• A 12-month study involving 101 patients with hypertension.
• Administration of Estulic as monotherapy or in combination with other antihypertensive drugs.
• Monitoring of blood pressure, laboratory parameters, and subjective patient complaints.

Main Results:

• Estulic demonstrated effectiveness in monotherapy for mild hypertension and in combination therapy for moderate hypertension.
• Significant reduction in blood pressure was observed, with stabilization at lower levels.
• The number and dosage of previously administered drugs were reduced.
• No significant changes in laboratory parameters were noted.
• Improvement in subjective complaints was reported in 60% of patients.

Conclusions:

• Guanfacin (Estulic) is an effective drug for treating hypertension across various severity degrees.
• Favorable antihypertensive action, low incidence of side effects, and once-daily dosing contribute to its utility.
• Estulic facilitates the reduction of concomitant antihypertensive medications.